Scarica l'app Stockscreener
9.15
8.28%
0.70
Oric Pharmaceuticals Inc Borsa (ORIC) Ultime notizie
Oric Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.8% HigherShould You Buy? - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Biotech Gem with 148% Upside Potential - DirectorsTalk Interviews
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded by Piper Sandler to Strong-Buy Rating - MarketBeat
Why ORIC Pharmaceuticals Inc. stock attracts global investors2025 Price Targets & High Win Rate Trade Alerts - ulpravda.ru
Is ORIC Pharmaceuticals Inc. stock a buy before product launchesQuarterly Trade Report & Capital Efficient Trading Techniques - ulpravda.ru
Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policiesEarnings Miss & Stock Timing and Entry Methods - ulpravda.ru
Options Flow: Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policies2025 EndofYear Setup & Daily Technical Stock Forecast Reports - ulpravda.ru
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpWhat's Next? - MarketBeat
How ORIC Pharmaceuticals Inc. stock reacts to Fed rate cutsVolatility Trading Techniques & Superior Capital Trading Plans - ulpravda.ru
Piper Sandler Initiates Coverage on ORIC with Overweight Rating and $22 PT | ORIC Stock News - GuruFocus
Piper Sandler initiates ORIC Pharmaceuticals stock with Overweight rating By Investing.com - Investing.com Canada
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications - MSN
Squarepoint Ops LLC Invests $1.08 Million in Oric Pharmaceuticals, Inc. $ORIC - Defense World
(ORIC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) surges as intriguing ESMO Asia data for Enozertinib prompts Wells Fargo to assign higher value - MSN
Will ORIC Pharmaceuticals Inc. stock benefit from green energy trendsWatch List & AI Optimized Trading Strategy Guides - Улправда
Is ORIC Pharmaceuticals Inc. stock a buy on dipsDollar Strength & Growth-Oriented Investment Plans - DonanımHaber
Why retail investors favor ORIC Pharmaceuticals Inc. stockMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
How ORIC Pharmaceuticals Inc. stock reacts to job market dataExit Point & High Yield Stock Recommendations - DonanımHaber
Will ORIC Pharmaceuticals Inc. stock benefit from infrastructure spendingDividend Hike & Free Technical Confirmation Trade Alerts - DonanımHaber
Oric Pharmaceuticals (ORIC) Stock Analysis: Exploring a 157% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
How strong is ORIC Pharmaceuticals Inc. stock revenue growth2025 Momentum Check & AI Powered Market Entry Ideas - Улправда
ORIC Pharmaceuticals Earnings Notes - Trefis
Oric Pharmaceuticals (NASDAQ:ORIC) Insider Pratik Multani Sells 10,720 Shares - MarketBeat
Dominic Piscitelli Sells 10,720 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) CEO Sells 33,374 Shares - MarketBeat
[Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Oric Pharmaceuticals Executives Conduct Stock Transactions - TradingView — Track All Markets
Oric Pharmaceuticals President and CEO Sells Shares - TradingView — Track All Markets
Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 7.5%Here's What Happened - MarketBeat
CFO Piscitelli Files To Sell 10,720 Of Oric Pharmaceuticals Inc [ORIC] - TradingView — Track All Markets
ORIC Pharmaceuticals (ORIC) Surges as Intriguing ESMO Asia Data for Enozertinib Prompts Wells Fargo to Assign Higher Value - Insider Monkey
20 Stocks That Will Double in 2026 - Insider Monkey
Frazier Life Sciences Management L.P. Sells 344,859 Shares of Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals Advances Key Cancer Drug Toward Late-Stage Trials - AD HOC NEWS
Oric Pharmaceuticals, Inc. $ORIC Shares Sold by EcoR1 Capital LLC - MarketBeat
Alkeon Capital Management LLC Boosts Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Responsive Playbooks and the ORIC Inflection - Stock Traders Daily
Stempoint Capital LP Makes New Investment in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Dir Kunkel Acquires 10,000 Of Oric Pharmaceuticals Inc [ORIC] - TradingView — Track All Markets
Vivo Capital LLC Has $31.74 Million Stock Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Resolute Capital Asset Partners LLC Invests $2.31 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Wells Fargo maintains ORIC Pharmaceuticals (ORIC) overweight recommendation - MSN
ORIC Pharmaceuticals (ORIC) Sees Analyst Rating Update from Wells Fargo | ORIC Stock News - GuruFocus
Oric Pharmaceuticals' (ORIC) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Wedbush Reiterates 'Outperform' Rating for ORIC Pharmaceuticals - GuruFocus
Wells Fargo raises ORIC Pharmaceuticals stock price target on promising cancer drug data - Investing.com Canada
Oric Pharmaceuticals, Inc. Presents Enozertinib Program Update - TradingView
JPMorgan Chase & Co. Raises Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):